These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35228554)

  • 1. Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.
    Moon SS; Richter-Roche M; Resch TK; Wang Y; Foytich KR; Wang H; Mainou BA; Pewin W; Lee J; Henry S; McAllister DV; Jiang B
    NPJ Vaccines; 2022 Feb; 7(1):26. PubMed ID: 35228554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
    Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
    Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets.
    Wang Y; Vlasova A; Velasquez DE; Saif LJ; Kandasamy S; Kochba E; Levin Y; Jiang B
    PLoS One; 2016; 11(11):e0166038. PubMed ID: 27824918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.
    Donadei A; Kraan H; Ophorst O; Flynn O; O'Mahony C; Soema PC; Moore AC
    J Control Release; 2019 Oct; 311-312():96-103. PubMed ID: 31484041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch.
    Moon S; Wang Y; Edens C; Gentsch JR; Prausnitz MR; Jiang B
    Vaccine; 2013 Jul; 31(34):3396-402. PubMed ID: 23174199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms.
    Zhou Y; Wu J; Hu X; Chen R; Lin X; Yin N; Lu C; Ye J; Zhao Y; Song X; Song Z; Wang J; Li Y; Li J; Zhang G; Sun M; Li H
    Hum Vaccin Immunother; 2023 Dec; 19(1):2189598. PubMed ID: 36994772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study.
    Gillard P; Tamura T; Kuroki H; Morikawa Y; Moerman L; Parra J; Kitamura Y; Mihara K; Okamasa A
    Hum Vaccin Immunother; 2019; 15(4):800-808. PubMed ID: 30785851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
    Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
    J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of rhesus rotavirus vaccine given in combination with oral or inactivated poliovirus vaccines and diphtheria-tetanus-pertussis vaccine.
    Jalil F; Zaman S; Carlsson B; Glass RI; Kapikian AZ; Mellander L; Hanson LA
    Trans R Soc Trop Med Hyg; 1991; 85(2):292-6. PubMed ID: 1653474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.
    Ogra PL
    Ann N Y Acad Sci; 1995 May; 754():97-107. PubMed ID: 7625685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
    Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
    Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine.
    Halsey NA; Blatter M; Bader G; Thoms ML; Willingham FF; O'Donovan JC; Pakula L; Berut F; Reisinger KS; Meschievitz C
    Pediatr Infect Dis J; 1997 Jul; 16(7):675-9. PubMed ID: 9239772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
    Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines.
    Zhou Y; Hu X; Chen R; Wu J; Lin X; Lu C; Yin N; Tang Y; Shi P; Song Z; Zhao Y; Sun M; Li H
    Vaccine; 2022 Jun; 40(28):3843-3850. PubMed ID: 35644669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
    Kouiavskaia D; Mirochnitchenko O; Dragunsky E; Kochba E; Levin Y; Troy S; Chumakov K
    J Infect Dis; 2015 May; 211(9):1447-50. PubMed ID: 25391313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.
    Muller DA; Fernando GJP; Owens NS; Agyei-Yeboah C; Wei JCJ; Depelsenaire ACI; Forster A; Fahey P; Weldon WC; Oberste MS; Young PR; Kendall MAF
    Sci Rep; 2017 Oct; 7(1):12644. PubMed ID: 28974777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.